#AACE2021: Top 20-Personalized Treatment in Acromegaly

Video Transcription

Video Summary

In this video, Dr. Maria Flesseriu, a professor of medicine and neurological surgery, discusses the personalized treatment of acromegaly. She explains that acromegaly is a rare disease characterized by the excess production of growth hormone (GH) in adults. Dr. Flesseriu highlights the importance of achieving biochemical control in acromegaly to improve patient outcomes and quality of life. Surgery is typically the first-line treatment for acromegaly, but medical therapy is necessary for many patients due to late diagnosis or residual disease. Somatostatin receptor ligands, such as octreotide and lanreotide, are commonly used as first-line medical therapy. Pegvisomant, a GH receptor antagonist, and pasireotide, a multi-receptor targeted somatostatin receptor ligand, are alternative options for patients who do not achieve adequate control with somatostatin receptor ligands. Dr. Flesseriu also discusses the use of oral octreotide capsules as a new treatment option. Combination therapy may be necessary for some patients, and the choice of therapy depends on factors such as tumor characteristics, patient comorbidities, and treatment response. Dr. Flesseriu emphasizes the importance of individualizing treatment to each patient's specific needs and preferences. She also discusses the impact of treatment on quality of life and the potential for de-escalation of therapy in patients who experience tumor shrinkage. Overall, Dr. Flesseriu provides a comprehensive overview of the personalized treatment options for acromegaly, highlighting the need for ongoing monitoring and adjustment of therapy to achieve optimal outcomes for patients.

Asset Subtitle

Maria Fleseriu, MD, FACE | Irina Bancos, MD

Asset Caption

Slides unavailable

Keywords

acromegaly

personalized treatment

growth hormone

biochemical control

surgery

medical therapy

somatostatin receptor ligands

combination therapy

tumor characteristics

quality of life